Immunomedics announces plans to price public offering of common stock

Wells Fargo Securities and Jefferies are bookrunning managers for deal

By Devika Patel

Knoxville, Tenn., May 1 - Immunomedics, Inc. will conduct a public offering of common stock, according to a preliminary prospectus supplement filed Thursday with the Securities and Exchange Commission.

Wells Fargo Securities, LLC and Jefferies LLC are the joint bookrunning managers.

Proceeds will be used for clinical development, research and development activities, working capital and general corporate purposes.

Based in Morris Plains, N.J., Immunomedics develops monoclonal, antibody-based products used to treat cancer, autoimmune and other diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.